The Pharmacy Times® Heart Failure Resource Center is a comprehensive resource for clinical news and expert insights on treatments that address issues caused by the heart muscle not pumping blood as well as it should.
April 8th 2024
The finding did not reach statistical significance in the primary composite endpoint.
ENTRESTOâ„¢ (sacubitril/valsartan) for the Management of Heart Failure
March 31st 2016ENTRESTOâ„¢ (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg, from Novartis Pharmaceuticals Corporation, are a combination of an angiotensin receptor blocker and a novel neprilysin inhibitor, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association class II through IV) and reduced ejection fraction.
Read More